Nasus Pharma Ltd. (NSRX)
NYSE: NSRX · Pharmaceutical Preparations · Tel Aviv - Yafo, IL · filing with the SEC since 2024
Who runs Nasus Pharma Ltd.
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
O'Grady Brendan P.
Chief Executive Officer. First filing Jul 2026, latest Jul 31, 2026, 0 filings in all.
Officers reporting now
5
of 9 people with a filing in the last fifteen months
Directors reporting now
4
9 people on the record since 2026
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Elmaliah Oren | Interim CFO | Sep 2026 | Sep 23, 2026 | none |
| Rubin Eyal | Chief Financial Officer | Mar 2026 | Sep 21, 2026 | none |
| O'Grady Brendan P. | Chief Executive Officer | Jul 2026 | Jul 31, 2026 | none |
| Teleman Dan Benjamin | Chief Executive Officer | Mar 2026 | Jul 29, 2026 | none |
| Megiddo Dalia | Chief Development Officer | Mar 2026 | Mar 27, 2026 | none |
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Hershman Ronnie | director | Mar 2026 | Mar 27, 2026 | none |
| Israel Isaac | director | Mar 2026 | Mar 27, 2026 | none |
| Shacham Sharon | director | Mar 2026 | Mar 27, 2026 | none |
| Silberman David | director | Mar 2026 | Mar 27, 2026 | none |
Owners of more than 10% of a classsales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Gilboa Udi | other | Mar 2026 | Mar 27, 2026 | none |
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.